Horiuchi et al found that a potent NF‐κB inhibitor, nafamostat mesilate enhances the antitumor effect of GEM/nPTX chemotherapy for PC.33 Moreover, inhibition of tripartite motif containing 31 (TRIM31) could reduce NF‐κB signaling and subsequently inactivate various antiapoptosis genes, which can enhance GEM efficiency in PDAC.30 The gene discussed is TRIM31; the disease is pachyonychia congenita.